Delirium in advanced cancer is often poorly identified and inappropriately managed. It is one of the most common causes for admission to clinical institutions and is the most frequently cited psychiatric disorder in terminal cancer. Diagnosis of delirium is defined as a disturbance of consciousness and attention with a change in cognition and/or perception. In addition, it develops suddenly and follows a fluctuating course and it is related to other causes, such as cancer, metabolic disorders or the effects of drugs. Delirium occurs in 26% to 44% of cancer patients admitted to hospital or hospice. Of all advanced cancer patients, over 80% eventually experience delirium in their final days. In advanced cancer, delirium is a multifactorial syndrome where opioids factor in almost 60% of episodes. Delirium in such patients, excluding terminal delirium, may be reversible in 50% of cases. Providing adequate end-of-life care for a patient with delirium is the main challenge. The family needs advice and it is important to create a relaxing environment for the patient. The primary therapeutic approach is to identify the reversible causes of delirium. Some therapeutic strategies have been shown to be effective: reduction or withdrawal of the psychoactive medication, opioid rotation, and hydration. Haloperidol is the most frequently used drug, and new neuroleptics such as risperidone or olanzapine are being tested with good results. Methylphenidate has been used for hypoactive delirium.
Casarett DJ, Inouye SK. Diagnosis and management of delirium near the end of life. Ann Intern Med2001; 135: 32–40.
3.
Ross DD, Alexander CS. Management of common symptoms in terminally ill patients. Constipation, delirium and dyspnea. Am Fam Physician2001; 64: 1019–1026.
4.
Ingham JM, Caraceni AT. Delirium. In Berger Am, Portenoy RK, Weissman R eds. Principles and practice of supportive oncology. Philadelphia: Lippincott-Raven Publishers, 1998: 477–495.
5.
Cobb JL, Glantz MJ, Nicholas PK, et al. Delirium in patients with cancer at the end of life. Cancer Pract2000; 8: 172–177.
6.
Minagawa H, Uchitomi Y, Yamawaki S, et al. Psychiatric morbidity in terminally ill cancer patients. A prospective study. Cancer1996; 78: 1131–1137.
7.
McDonald AJD. Delirium. In Tallis R, Fillit H, Brock-lehurst JC eds. Brocklehurst's textbook of geriatric medicine and gerontology, 5th ed.Edinburgh: Livingstone, 1998: 685–700.
8.
Gallinat J, Moller H, Moser RL, et al. Postoperative delirium: risk factors, prophylaxis and treatment. Anaesthesist1999; 48: 507–518.
9.
Karlsson I. Drugs that induce delirium. Dement Geriatr Cogn Disord1999; 10: 412–415.
10.
American Psychiatric Association. Practice guidelines for the treatment of patient with delirium. Washington DC: American Psychiatric Association, 1999.
11.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington DC: American Psychiatric Association, 1994.
12.
Lawlor PG. The panorama of opioid-related cognitive dysfunction in patients with cancer. Cancer2002; 94: 1836–1853.
13.
Caraceni A. Delirium in palliative care. Eur J Palliat Care1995; 2: 62–67.
14.
Akechi T, Nakano T, Okamura H, et al. Psychiatric disorders in cancer patients: descriptive analysis of 1721 psychiatric referrals at two Japanese cancer center hospitals. Jpn J Clin Oncol2001; 31: 188–194.
15.
Bruera E, Miller L, McCallion J, et al. Cognitive failure in patients with terminal cancer: a prospective study. J Pain Symptom Manage1992; 7: 192–195.
16.
Morita T, Tei Y, Tsunoda J, Inoue M, Chihara S. Underlying pathologies and their associations with clinical features in terminal delirium of cancer patients. J Pain Symptom Manage2001; 22: 997–1006.
17.
Lawlor PG, Gagnon B, Mancini IL, et al. Delirium as a predictor of survival in older patients with advanced cancer. Arch Intern Med2000; 160: 2866–2868.
18.
Gagnon P, Allard P, Masse B, DeSerres M. Delirium in terminal cancer: a prospective study using daily screening, early diagnosis, and continuous monitoring. J Pain Symptom Manage2000; 19: 412–426.
19.
Sarhill N, Walsh D, Nelson KA, LeGrand S, Davis MP. Assessment of delirium in advanced cancer: the use of the bedside confusion scale. Am J Hosp Palliat Care2001; 18: 335–341.
20.
Caraceni A, Nanni O, Maltoni M, et al. Impact of delirium on the short term prognosis of advanced cancer patients. Cancer2000; 89: 1145–1149.
21.
Pirovano M, Maltoni M, Nanni O, et al. A new palliative prognostic score: a ” rst step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. J Pain Symptom Manage1999; 17: 231–239.
Trzepacz PT. Is there a ” nal common neural pathway in delirium? Focus on acetylcholine and dopamine. Semin Clin Neuropsychiatry2000; 5: 132–148.
24.
Brown TM. Drug-induced delirium. Semin Clin Neuropsychiatry2000; 5: 113–124.
25.
Reyes-Ortiz CA, Largo U, Cárdenas JP. Sǵndrome confusional agudo en un nonagenario hospitalizado. Colombia Médica1998; 29: 158–161.
26.
Cheng C, Roemer-Becuwe C, Pereira J. When midazolam fails. J Pain Symptom Manage2002; 23: 256–265.
27.
Tuma R, DeAngelis LM. Altered mental status in patients with cancer. Arch Neurol2000; 57: 1727–1731.
28.
Moss JH, Lanctot KL. Iatrogenic benzodiazepine withdrawal delirium in hospitalized older patients. J Am Geriatr Soc1998; 46: 1020–1022.
29.
Lipowski ZJ. Update on delirium. Psychiatr Clin North Am1992; 15: 335–346.
30.
Keeley PW, Foster G, Whitelaw L. Hear my song: auditory hallucinations with tramadol hydrochloride. BMJ2000; 321: 1608-1608.
31.
Fountain A. Visual hallucinations: a prevalence study among hospice inpatients. Palliat Med2001; 15: 19–25.
32.
Coyle N, Breitbart W, Weaver S, Portenoy R. Delirium as a contributing factor to crescendo pain: three case reports. J Pain Symptom Manage1994; 9: 44–47.
33.
Breitbart W, Gibson C, Tremblay A. The delirium experience: delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/ caregivers, and their nurses. Psychosomatics2002; 43: 183–194.
34.
Cherny NI, Coyle N, Foley KM. Suffering in the advanced cancer patient: a de” nition and taxonomy. J Palliat Care1994; 10: 57¡70.
35.
Fainsinger RL, Tapper M, Bruera E. A perspective on the management of delirium in terminally ill patients on a palliative care unit. J Palliat Care1993; 9: 4–8.
36.
Inouye SK, Foreman MD, Mion LC, et al. Nurses' recognition of delirium and its symptoms: comparison of nurse and researcher ratings. Arch Intern Med2001; 161: 2467–2473.
37.
Schuurmans MJ, Duursma SA, Shortridge-Baggett LM. Early recognition of delirium: review of the literature. J Clin Nurs2001; 10: 721–729.
38.
Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12: 189–198.
39.
Lobo A, Saz P, Marcos G, et al. Revalidation and standardization of the Cognition Mini-Exam (” rst Spanish version of the Mini-Mental Status Examination) in the general geriatric population. Med Clin (Barc)1999; 112: 767–774.
40.
Lobo A. Screening de trastornos psíquicos en la práctica médica. Zaragoza: Secretariado de Publicaciones, Universidad de Zaragoza, 1987.
41.
Breibart W, Rosen‘ d B, Roth A, et al. The Memorial Delirium Assessment Scale. J Pain Symptom Manage1997; 13: 128–137.
42.
Lawlor PG, Nekolaichuk C, Gagnon B, et al. Clinical utility, factor analysis, and further validation of the Memorial Delirium Assessment Scale in patients with advanced cancer: assessing delirium in advanced cancer. Cancer2000; 88: 2859–2867.
43.
Trzepacz P, Baker R, Greenhouse J. A symptom rating scale for delirium. Psychiatry Res1988; 23: 89–97.
44.
Morita T, Tsunoda J, Inoue S, Chihara S, Oka K. Communication Capacity Scale and Agitation Distress Scale to measure the severity of delirium in terminally ill cancer patients: a validation study. Palliat Med2001; 15: 197–206.
45.
Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol2002; 20: 348–352.
46.
Fainsinger RL, MacEachern T, Miller MJ, et al. The use of hypodermoclysis for rehydration in terminally ill cancer patients. J Pain Symptom Manage1994; 9: 298–302.
47.
Simon L, Jewell N, Brokel J. Management of acute delirium in hospitalized elderly: a process improvement project. J Geriatr Nurs1997; 18: 1504-1504.
48.
Morency CR. Mental status change in the elderly: recognizing and treating delirium. J Prof Nurs1990; 6: 356–364.
49.
Foreman MD, Mion LC, Tryostad L, et al. Standard of practice protocol: acute confusion/delirium. NICHE Faculty. J Geriatr Nurs1999; 20: 147–152.
50.
Driver LC, Bruera E. Delirium. In Driver LC, Bruera E eds. The MD Anderson palliative care handbook. Houston: The University of Texas, 2000; 95–99.
51.
Platt MM, Breitbart W, Smith M, et al. Ef” cacy of neuroleptics for hypoactive delirium. J Neuropsychiatry Clin Neurosci1994; 6: 66–67.
52.
Mazzocato C, Stiefel F, Buclin, T et al. Psychopharmacology in supportive care of cancer: a review for the clinician. Neuroleptics. Support Care Cancer2000; 8: 89–97.
53.
Breitbart W. Diagnosis and management of delirium in terminally ill. In Bruera E, Portenoy R eds. Topics in palliative care. Volume 5. New York: Oxford University Press, 2001; 303–321.
54.
Lee MA, Leng ME, Tiernan EJ. Risperidone: a useful adjunct for behavioural disturbance in primary cerebral tumours. Palliat Med2001; 15: 255–256.
55.
Kiraly SJ, Gibson RE, Ancill RJ, Holliday SG. Risperidone: treatment response in adult and geriatric patients. Int J Psychiatry Med1998; 28: 255–263.
56.
Ravona-Springer R, Dolberg OT, Hirschmann S, Grunhaus L. Delirium in elderly patients treated with risperidone: a report of three cases. J Clin Psychopharmacol1998; 18: 171–172.
57.
Sipahimalani A, Masand PS. Use of risperidone in delirium: case reports. Ann Clin Psychiatry1997; 9: 105–107.
58.
Breitbart W, Tremblay A, Gibson C. An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics2002; 43: 175–182.
59.
Davis MP, Dickerson ED. Olanzapine: another psycho-tropic?Am J Hosp Palliat Care2001; 18: 129–132.
60.
Passik SD, Cooper M. Complicated delirium in a cancer patient successfully treated with olanzapine. J Pain Symptom Manage1999; 17: 219–223.
61.
Breibart W, Marotta R, Platt M, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry1996; 6: 231–237.
62.
Fainsinger RL, Waller A, Bercovici M, et al. A multi-centre international study of sedation for uncontrolled symptoms in terminally ill patients. Palliat Med2000; 14: 257–265.
63.
TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003; 327: 708–713.
64.
Stirling LC, Kurowska A, Tookman A. The use of phenobarbitone in the management of agitation and seizures at the end of life. J Pain Symptom Manage1999; 17: 363–368.
65.
Morita T, Otani H, Tsunoda J, et al. Successful palliation of hypoactive delirium due to multi-organ failure by oral methylphenidate. Support Care Cancer2000; 8: 134–137.
66.
Francis J, Martin D, Kapoor WN. A prospective study of delirium in hospitalized elderly. JAMA1990; 263: 1097–1101.
67.
Levkoff SE, Evans DA, Liptzin B, et al. Delirium: the occurrence and persistence of symptoms among elderly hospitalized patients. Arch Intern Med1992; 152: 334–340.
68.
O'Keeffe S, Lavan J. The prognostic signi” cance of delirium in older hospital patients. J Am Geriatr Soc1997; 45: 174–178.
69.
Metitieri T, Bianchetti A, Trabucchi M. Delirium as a predictor of survival in older patients with advanced cancer. Arch Intern Med2000; 160: 2866–2868.
70.
Marcantonio ER, Flacker JM, Wright RJ, Resnick NM. Reducing delirium after hip fracture: a randomized trial. J Am Geriatr Soc2001; 49: 516–522.
